Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 6/20 | 0.51 |
| ▸ | GAK | O14976 | 2/20 | 0.47 |
| ▸ | RIPK2 | O43353 | 2/20 | 0.47 |
| ▸ | COQ8A | Q8NI60 | 2/20 | 0.47 |
| ▸ | NLK | Q9UBE8 | 2/20 | 0.47 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.46 |
| ▸ | CDK9 | P50750 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | PDE5A | O76074 | 1/20 | 0.42 |
| ▸ | KDM5A | P29375 | 1/20 | 0.42 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.42 |
| ▸ | EGLN1 | Q9GZT9 | 4/20 | 0.41 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.41 |
| ▸ | CDK8 | P49336 | 1/20 | 0.40 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9909156 | 0.90 | SCN9A (0.49) | SCN9AGAKRIPK2COQ8ANLK | |
| SCHEMBL9909299 | 0.85 | SCN9A (0.45) | SCN9AGAKRIPK2COQ8ANLK | |
| SCHEMBL9909216 | 0.84 | EGLN2 (0.47) | GAKRIPK2COQ8ANLKALOX15 | |
| SCHEMBL9909202 | 0.82 | HTT (0.51) | SCN9ACCNT1CDK9ALOX15HTT | |
| SCHEMBL12875034 | 0.81 | SCN9A (0.43) | SCN9AGAKRIPK2COQ8ANLK | |
| SCHEMBL9909169 | 0.81 | PDE5A (0.45) | SCN9APDE5AEGLN1MRGPRX4 | |
| SCHEMBL16509518 | 0.80 | CYP11B1 (0.43) | SCN9AEGLN1MRGPRX4 | |
| SCHEMBL16502433 | 0.80 | PLAU (0.49) | SCN9AEGLN1MRGPRX4 | |
| SCHEMBL9909186 | 0.79 | ALOX15 (0.48) | CCNT1CDK9ALOX15HTTTGFBR1 | |
| SCHEMBL6301162 | 0.78 | ALOX15 (0.57) | ALOX15HTTTGFBR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8853242-B2 | Nitrogenous-ring acylguanidine derivative | ASTELLAS PHARMA INC. (JP) | 2014-10-07 | — | — | US | disclosed |
| EP-2463276-A1 | NITROGENOUS-RING ACYLGUANIDINE DERIVATIVE | Astellas Pharma Inc. (JP) | 2012-06-13 | — | — | EP | disclosed |
| US-20120142727-A1 | NITROGENOUS-RING ACYLGUANIDINE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2012-06-07 | — | — | US | disclosed |
| WO-2011016504-A1 | NITROGENOUS-RING ACYLGUANIDINE DERIVATIVE | アステラス製薬株式会社 (JP) | 2011-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142727-A1 | NITROGENOUS-RING ACYLGUANIDINE DERIVATIVE | HTR5A, HTR2A, HTR1E | SCN9A 412/4885GAK 1532/4885RIPK2 2038/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.